NewAmsterdam Pharma Co N.V. (NAMS) stock
NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
$19.39−0.07 (-0.36%)
Close on Nov 17, 2026Market cap $2.32BP/E –Yield –
NewAmsterdam Pharma r&d expenses
Research and development expenses are spending on new products and technology.
NewAmsterdam Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $149.25M, up 4.5% year over year. For fiscal 2025 it was $141.83M, down 6.3% from the year before. The highest annual figure on record is $159.42M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.83M | -6.3% |
| FY2024 | Dec 31, 2024 | $151.41M | -5.0% |
| FY2023 | Dec 31, 2023 | $159.42M | +83.8% |
| FY2022 | Dec 31, 2022 | $86.74M | +199.4% |
| FY2021 | Dec 31, 2021 | $28.97M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $41.67M | +51.5% |
| Q1 FY2026 | Mar 31, 2026 | $38.01M | -15.1% |
| Q4 FY2025 | Dec 31, 2025 | $38.59M | +10.6% |
| Q3 FY2025 | Sep 30, 2025 | $30.97M | -13.3% |
| Q2 FY2025 | Jun 30, 2025 | $27.52M | -28.3% |
| Q1 FY2025 | Mar 31, 2025 | $44.75M | +5.5% |
| Q4 FY2024 | Dec 31, 2024 | $34.90M | -15.5% |
| Q3 FY2024 | Sep 30, 2024 | $35.70M | -17.7% |
| Q2 FY2024 | Jun 30, 2024 | $38.38M | +11.8% |
| Q1 FY2024 | Mar 31, 2024 | $42.43M | +5.0% |
| Q4 FY2023 | Dec 31, 2023 | $41.29M | – |
| Q3 FY2023 | Sep 30, 2023 | $43.37M | – |
| Q2 FY2023 | Jun 30, 2023 | $34.34M | – |
| Q1 FY2023 | Mar 31, 2023 | $40.42M | – |
See a number that looks wrong?